A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
A phase IIb, multicentre, open label study to evaluate the effectiveness, safety, and
tolerability of intratumoural tigilanol tiglate in adult participants with Stage IIIB to IV
M1c melanoma